Latest News and Press Releases

Positive nebokitug PSC Phase 2 data was presented in an oral session at BSG Live’25, the scientific meeting of the British Society for Gastroenterology.

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.

New patents in China and Russia further strengthen nebokitug's extensive intellectual property portfolio in the US, Europe and other major territories.

These major milestones in Q1 support advancement of Nebokitug to Phase 3 and position It to potentially become the first FDA-approved treatment for PSC.

Positive data from the Phase 2 SPRING trial of nebokitug in PSC was presented in an oral Distinguished Abstract Plenary session at DDW 2025

Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.

Clinical data on Chemomab's nebokitug for the treatment of PSC will be presented at the scientific conferences DDW25; EASL 2025 and BSG LIVE'25

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.

Many preclinical and patient sample studies and positive Phase 2 PSC data suggest nebokitug is potentially a promising new treatment for systemic sclerosis